The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1525
Brodalumab (Siliq) - Another IL-17A Antagonist for Psoriasis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved brodalumab (Siliq – Valeant), an injectable human interleukin (IL)-17A receptor antagonist, for treatment of adults with moderate to severe plaque psoriasis who have failed to respond to other systemic therapies. Brodalumab is the third IL-17A antagonist to be approved in the US for this indication; secukinumab (Cosentyx) and ixekizumab (Taltz) were approved earlier.1,2

STANDARD TREATMENT — Plaque psoriasis is a chronic, inflammatory, immune-mediated skin condition. Mild to moderate psoriasis is generally treated with topical corticosteroids. Topical vitamin D analogs and the retinoid tazarotene (Tazorac, and others) are alternatives that can be used alone or in combination with topical corticosteroids.3 For patients with moderate to severe disease, systemic options include ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Brodalumab (Siliq) - Another IL-17A Antagonist for Psoriasis
Article code: 1525b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian